Symjepi is a drug owned by Adamis Pharmaceuticals Corp. It is protected by 1 US drug patent filed in 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 20, 2036. Details of Symjepi's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11141540 | Syringe devices |
Oct, 2036
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Symjepi's patents.
Latest Legal Activities on Symjepi's Patents
Given below is the list of recent legal activities going on the following patents of Symjepi.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed Critical | 12 Oct, 2021 | US11141540 |
| Patent Issue Date Used in PTA Calculation Critical | 12 Oct, 2021 | US11141540 |
| Email Notification Critical | 23 Sep, 2021 | US11141540 |
| Issue Notification Mailed Critical | 22 Sep, 2021 | US11141540 |
| Application Is Considered Ready for Issue Critical | 14 Sep, 2021 | US11141540 |
| Dispatch to FDC | 14 Sep, 2021 | US11141540 |
| Issue Fee Payment Received Critical | 10 Sep, 2021 | US11141540 |
| Issue Fee Payment Verified Critical | 10 Sep, 2021 | US11141540 |
| Email Notification Critical | 11 Jun, 2021 | US11141540 |
| Electronic Review Critical | 11 Jun, 2021 | US11141540 |
US patents provide insights into the exclusivity only within the United States, but Symjepi is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Symjepi's family patents as well as insights into ongoing legal events on those patents.
Symjepi's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Symjepi's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 20, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Symjepi Generic API suppliers:
Epinephrine is the generic name for the brand Symjepi. 4 different companies have already filed for the generic of Symjepi, with Am Regent having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Symjepi's generic
Alternative Brands for Symjepi
Symjepi which is used for treating severe allergic reactions or anaphylaxis., has several other brand drugs using the same active ingredient (Epinephrine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Armstrong Pharms |
| |||
| Ars Pharms Operation |
| |||
| Baxter Hlthcare Corp |
| |||
| Bpi Labs |
| |||
| Endo Operations |
| |||
| Impax |
| |||
| Inforlife |
| |||
| Kaleo Inc |
| |||
| Long Grove Pharms |
| |||
| Mylan Speciality Lp |
| |||
| Vyteris |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Epinephrine, Symjepi's active ingredient. Check the complete list of approved generic manufacturers for Symjepi
About Symjepi
Symjepi is a drug owned by Adamis Pharmaceuticals Corp. It is used for treating severe allergic reactions or anaphylaxis. Symjepi uses Epinephrine as an active ingredient. Symjepi was launched by Adamis Pharms Corp in 2018.
Approval Date:
Symjepi was approved by FDA for market use on 27 September, 2018.
Active Ingredient:
Symjepi uses Epinephrine as the active ingredient. Check out other Drugs and Companies using Epinephrine ingredient
Treatment:
Symjepi is used for treating severe allergic reactions or anaphylaxis.
Dosage:
Symjepi is available in solution form for intramuscular, subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.3MG/0.3ML (0.3MG/0.3ML) | SOLUTION | Prescription | INTRAMUSCULAR, SUBCUTANEOUS |
| 0.15MG/0.3ML (0.15MG/0.3ML) | SOLUTION | Discontinued | INTRAMUSCULAR, SUBCUTANEOUS |